ArticlePLoS neglected tropical diseases2026
A six-pronged approach to manage a Plasmodium vivax outbreak in a low- and middle-income country on the road to malaria elimination.
Article in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond elimination; addressing challenges in maintaining the malaria elimination status in Suriname.Malaria journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMalaria remains a global health concern, with Plasmodium vivax as predominant species in the Americas. The region has made notable strides in reducing malaria incidence, but challenges persist. Guiana Shield countries share similar malaria ecologies and vector dynamics, yet their progress toward elimination is quite different. Suriname, a low-middle income country, has pursued malaria elimination and became the first Amazonian country to receive malaria-free certification in June 2025. However, the reintroduction through imported cases from neighboring countries with higher endemicity remains a serious threat, as exemplified by the 2019 outbreak in Pelele Tepoe. The response strategy and operational measures implemented to address this P. vivax outbreak are described, along with key lessons for effective outbreak management.
methodsThis descriptive study examines Suriname's most recent P. vivax outbreak, using surveillance and intervention data from November 2019 to August 2021. It outlines the rationale for employing an adaptive, multi-pronged outbreak management strategy, details implementation of approaches, tailored to evolving outbreak circumstances and evaluates the effectiveness of subsequent interventions. Factors contributing to the outbreak's prolonged duration, including COVID-19 pandemic impact are discussed, along with the resulting adaptations in the targeted responses.
resultsThe P. vivax outbreak lasted 22 months, resulting in 179 infections among 153 patients. Traditional strategies with corresponding interventions were introduced at onset, including "1-3-7" surveillance, community education and engagement and vector control. Continuous trend monitoring guided the adoption of additional less conventional and innovative measures, including mass screen-and-treat, mass drug administration (MDA), parasite genotyping and targeted treatment. Mass screen-and-treat was less effective in reducing parasite prevalence than MDA. Directly observed treatment reached 95.1% efficacy by day 180, however, relapses appeared to fuel the outbreak. Implementation of the "Radical Cure" marked the end of the outbreak.
conclusionsThe described adaptive, integrated, six-pronged approach, combining conventional strategies with targeted accelerator methods and inclusive stakeholder engagement can effectively control outbreaks in low-endemic or near-elimination regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.